SEC Filing Summary
Filing identity: The supplied filing is Transgenomic, Inc.’s Form 10-Q for the quarter ended June 30, 2011—not a filing identified as Precipio, Inc. The company-name mismatch should be verified.
Business context and reporting period
Transgenomic reported results for the three and six months ended June 30, 2011, compared with the same periods in 2010. Its businesses are Laboratory Services—including clinical genetic testing and pharmacogenomics research—and an Instrument Related Business selling bioinstruments and consumables. Laboratory Services results include the FAMILION genetic-testing business acquired in December 2010.
Financial performance and position
| Metric | Q2 2011 | Q2 2010 | Six months 2011 | Six months 2010 |
|---|---|---|---|---|
| Net sales | $7.667m | $5.095m | $15.148m | $10.537m |
| Gross profit | $4.555m | $2.487m | $8.742m | $5.371m |
| Gross margin | 59% | 49% | 58% | 51% |
| Operating loss | $1.624m | $1.058m | $2.374m | $1.432m |
| Net loss | $5.998m | $1.146m | $8.776m | $1.469m |
| Net loss available to common stockholders | $6.265m | $1.146m | $9.303m | $1.469m |
| Loss per common share | $0.13 | $0.02 | $0.19 | $0.03 |
Cash flow: Six-month operating cash flow was positive $0.087m, versus use of $0.027m in 2010. Investing activities used $0.355m and financing activities used $0.644m; cash declined $0.815m to $2.639m. Capital expenditures were $0.216m, and the company also reported additions to patents in its MD&A.
Liquidity and debt: At June 30, cash was $2.639m, working capital was $4.097m (down from $6.781m at December 31, 2010), and current assets and liabilities were $14.002m and $9.905m. Debt totaled $9.134m, including $1.728m current and $7.406m long term; the notes are secured by company assets. Total liabilities were $28.919m. Stockholders’ equity was only $0.111m, and redeemable Series A preferred stock was reported separately at $1.670m.
Other notable balance-sheet items: Net accounts receivable was $7.194m, after an allowance for doubtful accounts of $1.387m, up from $0.334m at year-end. Goodwill was $6.275m and net intangible assets were $8.522m.
Material changes versus prior comparable periods
- Six-month sales rose 44%, primarily reflecting the acquired FAMILION business and stronger Laboratory Services. Laboratory Services sales increased $6.111m; Instrument Related Business sales fell $1.500m, or 19%.
- In Q2, Laboratory Services revenue grew 292% year over year, while Instrument Related Business revenue declined 27%. The company sold one WAVE instrument in Q2 2011 versus 14 in Q2 2010.
- Gross margin improved, including a rise in six-month Laboratory Services margin from 36% to 56%. Operating losses nevertheless widened as selling, general and administrative expense increased, including acquisition-related costs, stock-based compensation, bad debt expense and acquired-intangible amortization.
- Net loss increased substantially due in part to $6.266m of non-cash preferred-stock revaluation expense for the six months, including $4.239m in Q2. The expense reflected increased fair value of the preferred-stock conversion feature and warrant liability.
- Six-month preferred dividends and accretion reduced income available to common stockholders by $0.527m. The preferred stock carries cumulative 10% dividends and specified investor rights, including board appointment rights.
Outlook, commentary, risks and contingencies
- Management expected existing liquidity to cover anticipated cash needs during 2011, but said long-term liquidity depends on increasing sales and reducing expenses through integration of FAMILION. It cautioned that it may not be able to achieve those aims or raise additional capital, and may not have sufficient liquidity to continue operations indefinitely.
- Management anticipated growth in diagnostics and laboratory services from expanded testing menus and technologies, including FAMILION, COLD-PCR, Ice COLD-PCR and BLOCker-Sequencing. These are forward-looking expectations, not reported outcomes or quantified guidance.
- Pharmacogenomics revenue can fluctuate with clinical-trial enrollment and project timing; management cautioned that a period’s results may not indicate future sales. The WAVE product line is mature and faces competition, and instrument sales declined.
- Foreign-currency movements, reimbursement levels, customer budgets, competition, funding availability and execution of cost-saving and integration plans were identified as risks. The filing also notes patent-defense legal costs.
- Management said ordinary-course claims were not expected to have a material adverse effect. Vendor purchase commitments were $1.3m; future operating-lease payments were also disclosed. No material subsequent events were reported.
- Management concluded disclosure controls and procedures were effective as of June 30, 2011, with no material changes to internal control over financial reporting during the quarter.
Key facts for investors to verify
- Confirm the issuer: the document names Transgenomic, Inc., although the request identifies Precipio, Inc.
- Assess whether FAMILION-driven growth and improved laboratory margins can be sustained, and whether they offset continued weakness in instrument sales.
- Review the quality and collectability of receivables, particularly the sharp increase in the doubtful-account allowance.
- Track cash usage, working capital, debt maturities and secured-note terms against management’s stated 2011 liquidity expectation.
- Evaluate the potential effects of preferred-stock dividends, conversion rights, warrants and fair-value remeasurement on common-stockholders’ interests and reported earnings.